Elixxer

Elixxer AAQS

The The AAQS of Elixxer (ELXR.H.V) as of Oct 23, 2026 is 4. In the previous year, The AAQS was 4.00 — a change of 0.00% (lower).

AAQS

4

YoY

0.00%

Last updated:

Elixxer has a current AAQS of 4.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Elixxer in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Elixxer AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2016
4.00 CAD
Jan 1, 2017
4.00 CAD
Jan 1, 2018
4.00 CAD
Jan 1, 2019
4.00 CAD
Jan 1, 2020
4.00 CAD
Jan 1, 2021
4.00 CAD
Jan 1, 2022
4.00 CAD
Jan 1, 2023
4.00 CAD
The Elixxer AAQS history
YEARAAQSYoY
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
4—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Elixxer Stock analysis

What does Elixxer do? Elixxer Ltd. invests in cannabis-related businesses licensed for cultivation, production, and sale of cannabis and cannabis-derived products. The company focuses on medical cannabis and specialty pharmaceutical products, growing and producing medical-grade cannabis for global markets. Its brands include Viridi, Easyjoint, Freia, Little Green Pharma (LGP), and One Premium Cannabis, which are used for CBD cosmetics, natural wellness products, and pharmaceutical applications. Elixxer targets medical and wellness segments through its subsidiaries in Australia, Canada, Switzerland, Italy, and Jamaica, where it operates cultivation, extraction, and production facilities for legal cannabis products. The company generates revenue through its portfolio of cannabis investments, including nutraceutical, cosmetics, and pharmaceutical segments. Its subsidiaries LGC Finance Limited, LGC Capital EU OU, and LGC Capital Spain S.L. support its global operations, while its brands cater to consumers seeking CBD-based wellness solutions and medical cannabis products. Elixxer's focus on medical cannabis and pharmaceutical applications drives its market positioning in the global cannabis industry. Elixxer Ltd. primarily serves medical and specialty cannabis markets, with a strong emphasis on pharmaceutical-grade products. Its investments span cultivation, extraction, and production facilities across multiple countries, enabling it to supply global markets with medical cannabis and CBD-derived products. The company's brands are positioned within the wellness and pharmaceutical sectors, targeting consumers and healthcare providers interested in natural and medical cannabis solutions. Elixxer is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Elixxer stock

The AAQS of Elixxer is 4 in 2023.

On Eulerpool you can find the complete historical development of The AAQS Elixxer since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Elixxer

All Key Metrics — Elixxer